window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 25, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Drug Development

  • Artificial Intelligence,Biologics & Biosimilars,Drug Development,Precision medicine,Research & Development

    Latent Labs unveils AI model Latent-X for instant, lab-validated protein binder design

    No-code platform opens early access to generative binder design with [...]

    August 1, 2025
  • Biologics & Biosimilars,Clinical Development,Drug Development,Movers & Shakers,Research & Development

    Meitheal strengthens leadership team with new chief medical officer and head of medical affairs

    Appointments reflect strategic focus on infectious disease and medical affairs [...]

    August 1, 2025
  • Biologics & Biosimilars,CDMOs & Manufacturing,Drug Development,Regulatory Affairs,Supply Chain & Logistics

    Symbiosis completes 1,000th batch of sterile injectable drug product

    Contract manufacturer Symbiosis Pharmaceutical Services has announced the completion of [...]

    July 31, 2025
  • Biologics & Biosimilars,Clinical Development,Drug Development,Rare Diseases,Regulatory Affairs

    FDA grants fast track to Nektar’s rezpegaldesleukin for severe alopecia areata

    Nektar Therapeutics has received FDA Fast Track designation for its [...]

    July 29, 2025
  • Biologics & Biosimilars,Drug Development,Global health,Partnerships & Funding,Regulatory Affairs,Research & Development

    Centauri Therapeutics secures $5.1M from CARB-X to advance ABX-01 to first-in-human trials

    Centauri aims to start first-in-human clinical study for broad-spectrum immunotherapy [...]

    July 29, 2025
  • Biologics & Biosimilars,CDMOs & Manufacturing,Drug Development,European biotech,Partnerships & Funding,Supply Chain & Logistics

    Ofichem expands drug substance capabilities with acquisition of Meribel Pharma Solutions’ Uppsala site in Sweden

    Acquisition enhances innovation offering and expands biotech footprint across Nordic [...]

    July 29, 2025
  • Clinical Development,Drug Development,Precision medicine,Research & Development,Technology and platforms

    AltPep data highlights potential of intranasal peptide for early-stage Alzheimer’s

    AltPep Corporation has presented new preclinical findings at the Alzheimer’s [...]

    July 28, 2025
  • Drug Development,Patient Centricity,Rare Diseases,Regulatory Affairs

    MHRA approves Biogen’s tofersen for ultra-rare genetic form of motor neurone disease

    The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has [...]

    July 28, 2025
  • Drug Development,Global health,Precision medicine,Rare Diseases,Research & Development,Technology and platforms

    First Arab human pangenome reveals millions of novel variants using long-read sequencing

    Study powered by PacBio HiFi sequencing offers new insight into [...]

    July 28, 2025
  • Clinical Development,Drug Delivery & Formulation,Drug Development,Movers & Shakers,Oncology,Precision medicine

    PhoreMost appoints Pfizer drug discovery veteran Dr Adam Gilbert to scientific advisory board

    Appointment strengthens expertise in targeted protein degradation as company advances [...]

    July 28, 2025
Previous141516Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • PRISM ALS initiative develops patient-derived stem cell models to improve ALS/MND drug discovery
    Categories: Clinical Development, Clinical Trials, Rare Diseases, Research & Development, Technology and platforms
  • Proxygen appoints Chiara Conti as chief scientific officer to support move into clinical-stage development
    Categories: Biotech, Drug discovery, Healthcare leadership, Movers & Shakers, Research & Development, Startups and innovations, Technology and platforms
  • Efzimfotase alfa shows mixed Phase 3 results in hypophosphatasia across pediatric and adult patients
    Categories: Clinical Development, Clinical Trials, Rare Diseases, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top